QUALIblood

🌺 Today, QUALIblood stand in solidarity with the millions of women affected by endometriosis. 📊 In Belgium alone, approximately 750,000 women suffer from this condition. 🩺 Currently, it takes more than 5 years for a diagnosis, during which many women endure significant pain and uncertainty. 💊 Available treatments for endometriosis in Belgium include hormonal therapies, pain management, and surgical interventions. 🔬 At Qualiblood, we are committed to improving the lives of these women by developing innovative solutions. We are running clinical studies to evaluate the performance of our biomarker, #nAPCsr, designed to measure the risk of thrombosis potentially linked to hormonal treatments. This test ensures that each woman receives the best and safest treatment tailored to her unique needs ❤️🩹 . Together, let's continue to raise awareness and support research for better health outcomes. 💪💜 #EndometriosisAwareness #Qualiblood #WomensHealth #Innovation #ThrombosisPrevention

🚨💊 Pills and Thrombosis ... What is the Risk?! 😮 Every year in Europe, the failure to detect coagulation disorders associated with the use of oral contraceptives is responsible for 22,000 cases of thrombosis! 🤓 Oral contraceptives are known to increase the risk of venous thromboembolism. The risk varies depending on the type of progestogen and the dose of estrogen in the contraceptive and on the patient profile. 🔬 QUALIblood has developed a blood test (#nACPsr) capable of identifying the thrombosis risk for each patient associated with the use of pills and is now partering with Diagnostica Stago to develop the #nAPCsr kit, to be implemented in the hospital labs. The team is currently conducting clinical trials to evaluate this biomarker in other indications/conditions and is looking for partners. 👋 Contact us if you want to have more information about our undergoing research! 📢 Do not hesitate to share this information with your loved ones who may be concerned about this risk to prevent thrombosis and talk to your doctor! 💻 Visit our website to have more information about the nAPCsr and how you can be tested! www.thrombopill.com

⚠️ Don't miss it ! Tomorrow at the ESG - European Society of Gynecology conference ! 11:45 - 14:00 | Contraception 🩸 Laure Morimont – The nAPCsr, the biomarker for CHC-associated thrombotic risk evaluation 💊 Jonathan Douxfils – Lower reporting of venous thromboembolic events with natural estrogen-based COCs compared to ethinylestradiol-containing pills: A disproportionality analysis of the Eudravigilance database 🌸 Jonathan Douxfils – Effect of E4/DRSP 15/3 mg on Hemostasis Parameters in Post-Menarchal Adolescents: A Phase 3 Multicentre Study

💪#together 🩷 #fuckcancer 🍀 #team Télévie LégiaPark

💫 Don't miss this opportunity to meet the team at ESG - European Society of Gynecology conference in Riga!

🚀 QUALIblood at ESG 2025 in Riga – Join the Conversation! 🚀 We’re excited to announce that QUALIblood will be attending the ESG 2025 congress! Jonathan Douxfils, Laure Morimont, Marie Didembourg, and Nathalie Donis will be there to share our latest research and engage in meaningful discussions on women's health, contraception, and thrombosis risk assessment. 📢 Our Presentations 📍 Wednesday, March 19 | 18:30 - 20:00 | Poster Session 🤰🏻 Marie Didembourg (P86) – Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 Omicron subvariant during pregnancy - A case series study 📍 Saturday, March 22 | 11:45 - 14:00 | Contraception 🩸 Laure Morimont – The nAPCsr, the biomarker for CHC-associated thrombotic risk evaluation 💊 Jonathan Douxfils – Lower reporting of venous thromboembolic events with natural estrogen-based COCs compared to ethinylestradiol-containing pills: A disproportionality analysis of the Eudravigilance database 🌸 Jonathan Douxfils – Effect of E4/DRSP 15/3 mg on Hemostasis Parameters in Post-Menarchal Adolescents: A Phase 3 Multicentre Study 💡 Join us for insightful discussions! We’re particularly eager to connect on the nAPCsr biomarker, a game-changer in assessing thrombotic risk for combined hormonal contraceptive users. Let’s explore how it can help practitioners optimize patient treatment. We’d also love to discuss our ongoing clinical studies and potential collaborations. 📅 Will you be at ESG 2025 next week? Let’s meet! #ESG2025 #Gynecology #Thrombosis #nAPCsr #ClinicalStudies #WomensHealth #Qualiblood

🇮🇹 𝗕𝗶𝗼-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝗶𝘀 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝗰𝗼𝗿𝗻𝗲𝗿! You want to know more about QUALIblood and how our bioanalytical services can leverage your product development 🧪 ? Just take a few minutes to meet our CEO Julie Winand and discuss about your project and needs 🤝 ☕ . Connect with her directly or schedule a meeting via the BIO-Europe partnering platform!

🌍 Today is International Women’s Day 💜 💭 At QUALIblood, we firmly believe that all women deserve access to effective contraception and medication, as well as safety! ➡️ Did you know that over 1 million women in Belgium are currently on hormonal treatments? These treatments are used for contraception, alleviating menopause symptoms, and managing conditions like endometriosis or breast cancer. However, the thrombotic risks associated with these treatments are often underestimated and overlooked. 💡 By testing thrombotic risk before prescribing with the #nAPCsr, every woman can make an informed choice about her health. 🔬 At QUALIblood, we are committed to scientific innovation and clinical research to ensure that every woman receives the care she deserves. 📢 As we launch various clinical studies to evaluate the relevance of nAPCsr, we are seeking partners to join us in this mission. ⚡ Together, let’s act for women’s health: test, protect, advance. ⚡ #WomensRights #WomensHealth #SafeContraception #Pill #nAPCsr #Endometriosis #Thrombosis #InformedChoice #IWD

📅 3-9 March: European Week for Prevention and Information on Endometriosis 🔎 1 in 10 women of reproductive age suffers from endometriosis. 🌸 Yet, it remains an invisible disease, often misunderstood and underdiagnosed. Many women endure years of heavy pain, dismissed as "normal period cramps," while their condition silently progresses. ⏳ The reality? 🩸 7 to 10 years on average to receive a diagnosis 🤕 70% of affected women experience chronic pain that can be disabling 💊 Hormonal treatments are often the first-line therapy but can carry side effects and impact blood clotting 🤰 1 in 3 women with endometriosis needs assisted reproductive technology (ART) to conceive Yet, despite these alarming numbers, research into diagnostic tools and personalized treatments remains insufficient. At QUALIblood, we are committed to bridging this gap. Our research focuses on how endometriosis and the treatments used to manage it, affect blood clotting and whether biomarkers like #nAPCsr could help assess thrombotic risk. 🤔 Why does this matter? Because women deserve treatments that are not just effective but also safe. 💡 Raising awareness is key. Endometriosis is not “just period pain”, it is a real public health issue. By improving diagnosis, treatment, and follow-up, a real difference can be made in the lives of millions of women. 🔬 At QUALIblood, we believe that scientific innovation and clinical research play a fundamental role in ensuring that every woman receives the care she deserves. QUALIblood remains committed to working alongside healthcare professionals to improve outcomes in women’s health. 📢 As we launch different clinical studies to evaluate the relevance of nAPCsr, we are looking for partners to join us in this mission. Let’s work together to advance research and improve care for women with endometriosis! 👉 Contact us at contact@qualiblood.eu #EndometriosisAwareness #WomensHealth #QUALIblood #Thrombosis #nAPCsr

Thank you Gesellschaft für Thrombose- und Hämostaseforschung e.V., GTH for the organisation and the high quality programmation! #TGA #Innovation #hemostasis #thrombosis #nAPCsr